First quarter | |
|
|
"Enzymatica's "The most important event of the quarter is the partnership with STADA. The agreement marks an important breakthrough for Enzymatica and opens opportunities in one of Europe's largest self-care markets.
Net sales for the quarter amounted to SEK 11.4 million (12.3). At the same time, results improved compared with the corresponding period last year."
Significant events during the quarter
Significant events after the quarter
No significant events have been reported after the quarter.
Other events during and after the quarter
On 8 April 2026, Enzymatica AB entered a three-year loan facility totalling SEK 8 million.
The full report is available at https://www.enzymatica.com/investors/financial-reports/
The information in this press release is such that Enzymatica is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on April 28, 2026, at 08:30 CEST.